This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into the recent data from the ACCORD Phase 3 Trial of Axsome's AXS-05 in Alzheimer’s Disease Agitation

Ticker(s): AXSM

Who's the expert?

Institution: University of Rochester

  • Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program.
  • Currently manages 150 patients with Alzheimer's Disease Agitation.
  • Site PI for studies with solanezumab, gantenerumab, lecanemab, aducanemab, donanemab, semorinemab, pepinemab, AL-002, ATH-1017, and simufilam.
  • Internationally recognized in clinical research and considered one of the leading experts in Alzheimer's disease and dementia.

Interview Goal
To discuss safety and efficacy of AXS-05 after recent ACCORD Phase 3 Trial data release

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.